These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 8340921)

  • 1. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
    Kubo K; Kohara Y; Imamiya E; Sugiura Y; Inada Y; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jul; 36(15):2182-95. PubMed ID: 8340921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
    Kubo K; Inada Y; Kohara Y; Sugiura Y; Ojima M; Itoh K; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jun; 36(12):1772-84. PubMed ID: 8510105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.
    Noda M; Shibouta Y; Inada Y; Ojima M; Wada T; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    Biochem Pharmacol; 1993 Jul; 46(2):311-8. PubMed ID: 8347154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.
    Cirillo R; Renzetti AR; Cucchi P; Guelfi M; Salimbeni A; Caliari S; Castellucci A; Evangelista S; Subissi A; Giachetti A
    Br J Pharmacol; 1995 Mar; 114(6):1117-24. PubMed ID: 7620700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
    Kubo K; Kohara Y; Yoshimura Y; Inada Y; Shibouta Y; Furukawa Y; Kato T; Nishikawa K; Naka T
    J Med Chem; 1993 Aug; 36(16):2343-9. PubMed ID: 8360879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
    Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.
    Cazaubon C; Gougat J; Bousquet F; Guiraudou P; Gayraud R; Lacour C; Roccon A; Galindo G; Barthelemy G; Gautret B
    J Pharmacol Exp Ther; 1993 May; 265(2):826-34. PubMed ID: 8496828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
    Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB
    J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl)sulfonylurea (HR 720).
    Deprez P; Guillaume J; Becker R; Corbier A; Didierlaurent S; Fortin M; Frechet D; Hamon G; Heckmann B; Heitsch H
    J Med Chem; 1995 Jun; 38(13):2357-77. PubMed ID: 7608902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist.
    Mochizuki S; Sato T; Furuta K; Hase K; Ohkura Y; Fukai C; Kosakai K; Wakabayashi S; Tomiyama A
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):22-9. PubMed ID: 7723348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CV-11974, the active metabolite of TCV-116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells.
    Sachinidis A; el-Haschimi K; Ko Y; Seul C; Düsing R; Vetter H
    Biochem Pharmacol; 1996 Jul; 52(1):123-6. PubMed ID: 8678895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydropyrimidine angiotensin II receptor antagonists.
    Atwal KS; Ahmed SZ; Bird JE; Delaney CL; Dickinson KE; Ferrara FN; Hedberg A; Miller AV; Moreland S; O'Reilly BC
    J Med Chem; 1992 Dec; 35(25):4751-63. PubMed ID: 1469703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
    Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
    Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.
    Huang HC; Reitz DB; Chamberlain TS; Olins GM; Corpus VM; McMahon EG; Palomo MA; Koepke JP; Smits GJ; McGraw DE
    J Med Chem; 1993 Jul; 36(15):2172-81. PubMed ID: 8340920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
    Ashton WT; Hutchins SM; Greenlee WJ; Doss GA; Chang RS; Lotti VJ; Faust KA; Chen TB; Zingaro GJ; Kivlighn SD
    J Med Chem; 1993 Nov; 36(23):3595-605. PubMed ID: 8246227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996).
    Sircar I; Hodges JC; Quin J; Bunker AM; Winters RT; Edmunds JJ; Kostlan CR; Connolly C; Kesten SJ; Hamby JM
    J Med Chem; 1993 Aug; 36(16):2253-65. PubMed ID: 8360871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W; Mauz AB; Van Meel JC; Entzeroth M
    Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.